Drug Industry Taking Bigger Role in Clinical Cancer Trials
TUESDAY, Oct. 1, 2024 -- Clinical trials sponsored by Big Pharma enrolled eight times as many patients as U.S.-government trials did between 2018 and 2022, new research shows.
The study -- conducted by researchers at Fred Hutch Cancer Center in Seattle -- underscores the lack of investment in federally funded studies and a growing reliance on industry research. The magnitude of the gap researchers identified took them by surprise.
"We recognized that industry was playing an increasing role in cancer clinical research compared to decades ago," said lead study author Joseph Unger, a health services researcher and biostatistician at Fred Hutch Cancer Center in Seattle. "But we didn't realize the difference was this dramatic."
The study, which relied on data from clinicaltrials.gov, looked at more than 26,000 cancer trials.
Compared to 2008-2012, the share of enrollments attributed to industry versus federal support rose from 4.8 to 9.6 in adults, and from 0.7 to 2.3 in children.
Federally funded studies provide demographic diversity, the study pointed out. The number of Black participants enrolled in government-supported research was three times that of industry-funded research.
The findings were published Sept. 27 in the Journal of Clinical Oncology.
The researchers noted that federally funded research looks beyond industry's focus on supporting new drug approvals, into combining treatment types and whether approved drugs work in other cancers, for example.
"Underinvestment in federally funded cancer clinical research results in missed opportunities for scientific, clinical and population advances," Unger said in a cancer center news release. "Federally funded clinical trials have contributed to more than 14 million life years gained over four decades and have helped improve clinical care guidelines for patients."
Researchers said both industry- and government-funded trials are important.
"Industry investment in cancer clinical research has accelerated precision oncology and cancer immunotherapy tremendously," Unger said, pointing to industry's role in new drug discovery. "However, with increased federal investment in cancer research as well, we could see even greater strides in treatment options for patients with cancer."
Sources
- Fred Hutch Cancer Center, news release, Sept. 27, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
California Votes To Ban PFAS ‘Forever Chemicals’ in Cookware, Other Items
MONDAY, Sept. 15, 2025 — Every time you reach for a nonstick pan, you could be using chemicals that are now on the chopping block in the state of California. Lawmakers have...
Recall: Bariatric Fusion Vitamins Pulled for Missing Child-Safe Caps
MONDAY, Sept. 15, 2025 — About 4,700 bottles of Bariatric Fusion iron-containing multivitamins have been recalled because packaging does not meet federal safety standards...
Ebola Vaccinations Begin in Congo After Deadly Outbreak
MONDAY, Sept. 15, 2025 — Health workers in southern Kasai province have started giving Ebola vaccines as officials race to contain the latest outbreak, the World Health...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.